Status:
COMPLETED
Do HMG CoA Reductase Inhibitors Affect Abeta Levels?
Lead Sponsor:
Seattle Institute for Biomedical and Clinical Research
Conditions:
Alzheimer's Disease
Aging
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
Recent evidence suggests that there is a significant overlap between AD and cerebrovascular disease. In fact, AD and cerebrovascular disease may share some of the same risk factors, including hypercho...
Detailed Description
Recent evidence suggests that there is a significant overlap between AD and cerebrovascular disease. In fact, AD and cerebrovascular disease may share some of the same risk factors, including hypercho...
Eligibility Criteria
Inclusion
- Total cholesterol \> 200, and/or LDL \> 130
- No cognitive impairment
- Statin-naive for at least one year
- Women must not be pregnant, nursing, or planning to become pregnant
Exclusion
- Back ailments which would hinder LP procedure
- Neurological disease, including stroke, Parkinson's disease, Multiple Sclerosis, uncontrolled epilepsy, history of severe head trauma
- Hepatic disease
- Renal insufficiency
- Unstable medical disease
- Severe pulmonary disease
- Severe cardiac disease
- Uncontrolled hypertension (greater than 160/90)
- Uncontrolled hyper/hypothyroidism
- History of blood clotting abnormalities or platelet abnormalities
- History of chronic major psychiatric disorders or presence of current major depressive disorder (by DSM-IV criteria)
- History of substance abuse within the past year
- Taking exclusionary medications
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2005
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00303277
Start Date
August 1 2002
End Date
April 1 2005
Last Update
April 13 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Puget Sound Health Care System
Seattle, Washington, United States, 98108